Double blind, placebo controlled trial of metronidazole in Crohn's disease.

L Sutherland, J Singleton, J Sessions, S Hanauer, E Krawitt, G Rankin, R Summers, H Mekhjian, N Greenberger, M Kelly

Department of Medicine, University of Calgary.

A double blind study compared the efficacy of metronidazole in two doses (20 mg/kg, 10 mg/kg) with placebo in patients with Crohn's disease. One hundred and five patients participated but only 56 completed the 16 week study -21 were withdrawn for deterioration of symptoms, 17 for adverse experiences, and 11 for protocol violation. Significant improvement in disease activity as measured by the Crohn's disease activity index (metronidazole 20 mg/kg, 97 units; metronidazole 10 mg/kg, 67 units; placebo -1 unit, p = 0.002) and serum orosomucoid (metronidazole 20 mg/kg/day, 49; 10 mg/kg/day, 38; placebo, -9, p = 0.001)) were detected. Changes in C reactive protein concentrations did not achieve significance when all three groups were considered but were significant when all metronidazole treated patients were grouped and compared with the placebo treated patients (0.8 v -0.9, p less than 0.05). Although patients receiving metronidazole 20 mg/kg/day had a greater improvement in disease activity than those receiving 10 mg/kg/day (difference 30 units (95% confidence intervals -27-87), the small sample size may have precluded the detection of statistical significance. Preliminary analysis suggests that metronidazole was more effective in patients with disease confined to the large intestine or affecting both small and large bowel than in those with small bowel disease only. There were no differences in remission rates between metronidazole and placebo treated patients. We conclude that metronidazole warrants further assessment in the treatment of patients with active Crohn's disease.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Akobeng, A K (2008). Crohn's disease: current treatment options. Arch. Dis. Child. 93: 787-792 [Abstract] [Full Text]  
• Subramanian, S., Roberts, C. L., Hart, C. A., Martin, H. M., Edwards, S. W., Rhodes, J. M., Campbell, B. J. (2008). Replication of Colonic Crohn's Disease Mucosal Escherichia coli Isolates within Macrophages and Their Susceptibility to Antibiotics. Antimicrob. Agents Chemother. 52: 427-434 [Abstract] [Full Text]  
• Kamada, N., Maeda, K., Inoue, N., Hisamatsu, T., Okamoto, S., Hong, K. S., Yamada, T., Watanabe, N., Tsuchimoto, K., Ogata, H., Hibi, T. (2008). Nonpathogenic Escherichia coli Strain Nissle 1917 Inhibits Signal Transduction in Intestinal Epithelial Cells. Infect. Immun. 76: 214-220 [Abstract] [Full Text]  
• Dilger, K., Fux, R., Rock, D., Morike, K., Gleiter, C. H. (2007). Effect of High-Dose Metronidazole on Pharmacokinetics of Oral Budesonide and Vice Versa: A Double Drug Interaction Study. J Clin Pharmacol 47: 1532-1539 [Abstract] [Full Text]  
• Qualls, J. E., Kaplan, A. M., van Rooijen, N., Cohen, D. A. (2006). Suppression of experimental colitis by intestinal mononuclear phagocytes. J. Leukoc. Biol. 80: 802-815 [Abstract] [Full Text]  
• Lindsay, J O, Whelan, K, Stagg, A J, Gobin, P, Al-Hassi, H O, Rayment, N, Kamm, M A, Knight, S C, Forbes, A (2006). Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. Gut 55: 348-355 [Abstract] [Full Text]  
• Travis, S P L, Stange, E F, Lemann, M, Oresland, T, Chowers, Y, Forbes, A, D'Haens, G, Kitis, G, Cortot, A, Prantera, C, Marteau, P, Colombel, J-F, Gionchetti, P, Bouhnik, Y, Tiret, E, Kroesen, J, Starlinger, M, Mortensen, N J, for the European Crohn's and Colitis Organisation, (2006). European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 55: i16-i35 [Abstract] [Full Text]  
• Ingrassia, I., Leplingard, A., Darfeuille-Michaud, A. (2005). Lactobacillus casei DN-114 001 Inhibits the Ability of Adherent-Invasive Escherichia coli Isolated from Crohn's Disease Patients To Adhere to and To Invade Intestinal Epithelial Cells. Appl. Environ. Microbiol. 71: 2880-2887 [Abstract] [Full Text]  
• Carter, M J, Lobo, A J, Travis, S P L (2004). Guidelines for the management of inflammatory bowel disease in adults. Gut 53: v1-v16 [Full Text]  
• Hoentjen, F, Harmsen, H J M, Braat, H, Torrice, C D, Mann, B A, Sartor, R B, Dieleman, L A (2003). Antibiotics with a selective aerobic or anaerobic spectrum have different therapeutic activities in various regions of the colon in interleukin 10 gene deficient mice. Gut 52: 1721-1727 [Abstract] [Full Text]  
• Koretz, R. L. (2003). Update in Gastroenterology. ANN INTERN MED 139: 352-358 [Full Text]  
• Dieleman, L A, Goerres, M S, Arends, A, Sprengers, D, Torrice, C, Hoentjen, F, Grenther, W B, Sartor, R B (2003). Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut 52: 370-376 [Abstract] [Full Text]  
• Bamias, G., Marini, M., Moskaluk, C. A., Odashima, M., Ross, W. G., Rivera-Nieves, J., Cominelli, F. (2002). Down-Regulation of Intestinal Lymphocyte Activation and Th1 Cytokine Production by Antibiotic Therapy in a Murine Model of Crohn's Disease. J. Immunol. 169: 5308-5314 [Abstract] [Full Text]  
• Podolsky, D. K. (2002). Inflammatory Bowel Disease. NEJM 347: 417-429 [Full Text]  
• Saitoh, S., Noda, S., Aiba, Y., Takagi, A., Sakamoto, M., Benno, Y., Koga, Y. (2002). Bacteroides ovatus as the Predominant Commensal Intestinal Microbe Causing a Systemic Antibody Response in Inflammatory Bowel Disease. CVI 9: 54-59 [Abstract] [Full Text]  
• Hooper, L. V., Gordon, J. I. (2001). Commensal Host-Bacterial Relationships in the Gut. Science 292: 1115-1118 [Abstract] [Full Text]  
• Rath, H. C., Schultz, M., Freitag, R., Dieleman, L. A., Li, F., Linde, H.-J., Scholmerich, J., Sartor, R. B. (2001). Different Subsets of Enteric Bacteria Induce and Perpetuate Experimental Colitis in Rats and Mice. Infect. Immun. 69: 2277-2285 [Abstract] [Full Text]  
• Masseret, E, Boudeau, J, Colombel, J F, Neut, C, Desreumaux, P, Joly, B, Cortot, A, Darfeuille-Michaud, A (2001). Genetically related Escherichia coli strains associated with Crohn's disease. Gut 48: 320-325 [Abstract] [Full Text]  
• Zareie, M., Singh, P. K., Irvine, E. J., Sherman, P. M., McKay, D. M., Perdue, M. H. (2001). Monocyte/Macrophage Activation by Normal Bacteria and Bacterial Products : Implications for Altered Epithelial Function in Crohn's Disease. Am. J. Pathol. 158: 1101-1109 [Abstract] [Full Text]  
• Caradonna, L., Amati, L., Magrone, T., Pellegrino, N.M., Jirillo, E., Caccavo, D. (2000). Invited review: Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance. Innate Immunity 6: 205-214 [Abstract]  
• Kennedy, R.J., Kirk, S.J., Gardiner, K.R. (2000). Promotion of a Favorable Gut Flora in Inflammatory Bowel Disease. JPEN J Parenter Enteral Nutr 24: 189-195 [Abstract]  
• Boudeau, J., Glasser, A.-L., Masseret, E., Joly, B., Darfeuille-Michaud, A. (1999). Invasive Ability of an Escherichia coli Strain Isolated from the Ileal Mucosa of a Patient with Crohn's Disease. Infect. Immun. 67: 4499-4509 [Abstract] [Full Text]  
• Rath, H. C., Wilson, K. H., Sartor, R. B. (1999). Differential Induction of Colitis and Gastritis in HLA-B27 Transgenic Rats Selectively Colonized with Bacteroides vulgatus or Escherichia coli. Infect. Immun. 67: 2969-2974 [Abstract] [Full Text]  
• Duchmann, R, May, E, Heike, M, Knolle, P, Neurath, M, zum Buschenfelde, K-H M. (1999). T cell specificity and cross reactivity towards enterobacteria, Bacteroides, Bifidobacterium, and antigens from resident intestinal flora in humans. Gut 44: 812-818 [Abstract] [Full Text]  
• Arndt, H, Palitzsch, K-D, Scholmerich, J (1998). Leucocyte endothelial cell adhesion in indomethacin induced intestinal inflammation is correlated with faecal pH. Gut 42: 380-386 [Abstract] [Full Text]  
• Hanauer, S. B. (1996). Inflammatory Bowel Disease. NEJM 334: 841-848 [Full Text]  
• Greenberg, G. R., Feagan, B. G., Martin, F., Sutherland, L. R., Thomson, A., Williams, C. N., Nilsson, L.-G., Persson, T., The Canadian Inflammatory Bowel Disease Study Grou, (1994). Oral Budesonide for Active Crohn's Disease. NEJM 331: 836-841 [Abstract] [Full Text]